DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Active ingredient: Sargramostim - Brands, Medical Use, Clinical Data

Brands, Medical Use, Clinical Data

Drug Category

  • Immunomodulatory Agents
  • Antineoplastic Agents
  • Anti-infective Agents

Dosage Forms

  • Solution (IV Infusion)
  • Solution (Subcutaneous Injection)

Brands / Synonyms

Colony-stimulating factor; CSF; GM-CSF; Granulocyte-macrophage colony-stimulating factor precursor; Immunex; Leucomax (Novartis); Leukine; Leukine (Berlex Laboratories Inc) ; Molgramostin


Human, recombinant GM-CSF, expressed in yeast. Glycoprotein that is 127 residues. Substitution of Leu23 leads to a difference from native protein.


For the treatment of cancer and bone marrow transplant


Sargramostim is used in the treatment of bone marrow transplant recipients or those exposed to chemotherapy an recovering from acut myelogenous leukemia, Leukine or GM-CSF is a hematopoietic growth factor which stimulates the survival, clonal expansion (proliferation) and differentiation of hematopoietic progenitor cells. GM-CSF is also capable of activating mature granulocytes and macrophages. After a bone marrow transplant or chemotherapy, patients have a reduced capacity to produce red and white blood cells. Supplementing them with external sources of GM-CSF helps bring the level of neutrophils back to normal so that they can better fight infections.

Mechanism of Action

Sargramostim binds to the Granulocyte-macrophage colony stimulating factor receptor (GM-CSF-R-alpha or CSF2R) which stimulates a JAK2 STAT1/STAT3 signal transduction pathway. This leads to the production of hemopoietic cells and neutrophils


Not Available


Not Available

Biotrnasformation / Drug Metabolism

Not Available


Not Available

Drug Interactions

Not Available

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017